Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
Abstract Background This study is designed to evaluate the main hypothesis that nafamostat mesilate with standard therapy improves the severity and mortality rate in patients with COVID-19 pneumonia. Methods We conduct a randomized, open type, multi-institute/center, 2-group clinical trial with COVI...
Guardado en:
Autores principales: | Kyunglan Moon, Kyung-Wook Hong, In-Gyu Bae |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/72069f30a36449dbb9ccdebb6b130649 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
por: Kun Li, et al.
Publicado: (2021) -
Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial
por: Qinwei Fu, et al.
Publicado: (2021) -
Multimodal brain imaging effect of “Adjust Zang-fu and Arouse Spirit” electroacupuncture on diabetic cognitive impairment: study protocol of a randomized, sham-controlled pilot trial
por: Lin Yao, et al.
Publicado: (2021) -
Occupational Performance Coaching With Parents to Promote Community Participation of Young Children With Developmental Disabilities: Protocol for a Feasibility and Pilot Randomized Control Trial
por: Chi-Wen Chien, et al.
Publicado: (2021) -
Trials
Publicado: (2006)